Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
J Hepatol. 2024 Feb;80(2):243-250. doi: 10.1016/j.jhep.2023.10.019. Epub 2023 Oct 26.
BACKGROUND & AIMS: Sub-Saharan African (SSA) ethnicity has been associated with a higher risk of hepatocellular carcinoma (HCC) among individuals with chronic hepatitis B in cross-sectional studies. However, the incidence of HCC and performance of HCC risk scores in this population are unknown.
We conducted an international multicenter retrospective cohort study of all consecutive HBV-monoinfected individuals of SSA or Afro-Surinamese (AS) ethnicity managed at sites in the Netherlands, the United Kingdom and Spain. We assessed the 5- and 10-year cumulative incidences of HCC in the overall study population, among different clinically relevant subgroups and across (m)PAGE-B subgroups. Next, we explored the different risk factors for HCC.
During a median follow-up of 8 years, we analyzed 1,473 individuals of whom 34 developed HCC. The 5- and 10-year cumulative incidences of HCC were 1% and 2.4%. The 10-year cumulative incidence of HCC was 0.7% among individuals without advanced fibrosis at baseline, compared to 12.1% among individuals with advanced fibrosis (p <0.001). Higher age (adjusted hazard ratio [aHR] 1.05), lower platelet count (aHR 0.98), lower albumin level (aHR 0.90) and higher HBV DNA log10 (aHR 1.21) were significantly associated with HCC development. The 10-year cumulative incidence of HCC was 0.5% among individuals with a low PAGE-B score, compared to 2.9% in the intermediate- and 15.9% in the high-risk groups (p <0.001).
In this unique international multicenter cohort of SSA and AS individuals with chronic hepatitis B, we observed 5- and 10-year cumulative HCC risks of 1% and 2.4%, respectively. The risk of HCC was negligible for individuals without advanced fibrosis at baseline, and among individuals with low baseline (m)PAGE-B scores. These findings can be used to guide HCC surveillance strategies.
Sub-Saharan African ethnicity has been associated with a higher risk of hepatocellular carcinoma among individuals with chronic hepatitis B. In this international multicenter cohort study of sub-Saharan African and Afro-Surinamese individuals living with chronic hepatitis B in Europe, we observed 5- and 10-year cumulative incidences of hepatocellular carcinoma of 1% and 2.4%, respectively. The risk was negligible among individuals without advanced fibrosis and a low baseline (m)PAGE-B score. These findings can be used to guide HCC surveillance strategies in this population.
在横断面研究中,撒哈拉以南非洲(SSA)族群与慢性乙型肝炎患者发生肝细胞癌(HCC)的风险增加相关。然而,该人群中 HCC 的发病率以及 HCC 风险评分的表现尚不清楚。
我们对在荷兰、英国和西班牙的研究点接受治疗的所有 SSA 或非裔苏里南(AS)族群的 HBV 单感染个体进行了一项国际多中心回顾性队列研究。我们评估了整个研究人群、不同临床相关亚组以及(m)PAGE-B 亚组中 HCC 的 5 年和 10 年累积发生率。接下来,我们探讨了 HCC 的不同危险因素。
在中位 8 年的随访期间,我们分析了 1473 名患者,其中 34 名患者发生 HCC。HCC 的 5 年和 10 年累积发生率分别为 1%和 2.4%。基线时无晚期纤维化的患者中 HCC 的 10 年累积发生率为 0.7%,而晚期纤维化患者的 HCC 累积发生率为 12.1%(p<0.001)。年龄较高(校正后的危险比[aHR] 1.05)、血小板计数较低(aHR 0.98)、白蛋白水平较低(aHR 0.90)和 HBV DNA log10 较高(aHR 1.21)与 HCC 发生显著相关。PAGE-B 评分低的患者中 HCC 的 10 年累积发生率为 0.5%,而中危和高危组分别为 2.9%和 15.9%(p<0.001)。
在这项针对患有慢性乙型肝炎的 SSA 和 AS 个体的独特的国际多中心队列研究中,我们观察到 HCC 的 5 年和 10 年累积发生率分别为 1%和 2.4%。基线时无晚期纤维化的患者以及基线时 PAGE-B 评分较低的患者中,HCC 的风险可忽略不计。这些发现可用于指导 HCC 监测策略。
撒哈拉以南非洲族群与慢性乙型肝炎患者发生肝细胞癌的风险增加相关。在这项针对欧洲慢性乙型肝炎患者的撒哈拉以南非洲和非裔苏里南人群的国际多中心队列研究中,我们观察到 HCC 的 5 年和 10 年累积发生率分别为 1%和 2.4%。无晚期纤维化和基线时 PAGE-B 评分低的患者中,风险可忽略不计。这些发现可用于指导该人群的 HCC 监测策略。